Abstract 5527: A novel fully human anti-TIGIT and PVRIG bispecific antibody that elicits potent anti-tumor efficacy in pre-clinical studies

提吉特 抗体 流式细胞术 癌症研究 T细胞 免疫系统 单克隆抗体 免疫学 化学 生物
作者
Shuang Dai,Weifeng Huang,Yuan Zhou,Shaogang Peng,Jiayi Si,Chao Wang,Xiaoniu Miao,Yingda Xu,Joanne Sun,Xiaolin Liu,Andy Tsun,Tianhang Zhai
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): 5527-5527
标识
DOI:10.1158/1538-7445.am2022-5527
摘要

Abstract Background: TIGIT (T-cell immunoglobulin and ITIM domain), which is primarily expressed on activated and 'exhausted' T and NK cells, is one of the promising 'next generation' immune checkpoint molecules. Engagement of TIGIT to its ligands (i.e., PVR and PVRL2) leads to inhibitory signaling in T cells, promoting functional exhaustion of tumor-infiltrating T lymphocytes. Anti-TIGIT monoclonal antibodies have shown clinical benefit when combined with anti-PD-L1 agents in NSCLC. However, the single-agent efficacy of anti-TIGIT therapies have been limited. PVRIG (PVR-related immunoglobulin domain containing), which is another coinhibitory receptor of the DNAM/TIGIT/CD96 nectin family, binds with high affinity to PVRL2 and suppresses T-cell function, and shows nonredundant inhibitory effects alongside the TIGIT/PVR/PVRL2 axis. Here, we report a fully-human anti-TIGIT × PVRIG bispecific antibody (anti-TIGIT × PVRIG biAb), which blocks both the PVRIG/PVRL2 and TIGIT/PVR/PVRL2 pathways, that maintains the efficacy of the combination of the two mono-agents. The anti-TIGIT × PVRIG biAb is also highly efficacious when combined with PD1/PD-L1 inhibitors in mouse tumor models. Methods: An anti-TIGIT × PVRIG biAb was generated through the fusing of a fully-human IgG targeting TIGIT with a wild type G1-Fc to a fully-human scFv at the c-terminus targeting PVRIG. Binding affinity and specificity analyses were studied by flow cytometry and biolayer interferometry. The co-binding of the anti-TIGIT × PVRIG biAb to TIGIT and PVRIG was detected by ELISA. The immunomodulatory functions of the anti-TIGIT × PVRIG biAb were evaluated using a luciferase reporter cell assay in vitro and human PBMC-based tumor models in vivo. Results: The anti-TIGIT × PVRIG biAb binds with high affinity to the extracellular domain of human TIGIT/PVRIG and can bind to TIGIT and PVRIG simultaneously. In a competition assay, the anti-TIGIT × PVRIG biAb efficiently blocked the interaction between TIGIT and PVR/PVRRL2, and PVRIG with PVRL2. In a luciferase reporter cell system, the anti-TIGIT × PVRIG biAb induced high levels of luciferase activity compared with the anti-TIGIT or anti-PVRIG mAbs alone. In vivo, the anti-TIGIT × PVRIG biAb demonstrated stronger anti-tumor efficacy than the anti-TIGIT and anti-PVRIG mAbs as monotherapies or combined with anti-PD-1 mAb. Conclusion: Our anti-TIGIT × PVRIG biAb, a fully human bispecific antibody, either alone or in combination with anti-PD-1 mAb promotes immune cell activation both in vitro and in vivo, supporting its clinical development for the treatment of human cancers. The molecule is currently under GLP-toxicity evaluation in NHP, and a first-in-human study is expected to begin in 2022. Citation Format: Shuang Dai, Weifeng Huang, Zhijun Yuan, Shaogang Peng, Jiayi Si, Chao Wang, Xiaoniu Miao, Yingda Xu, Joanne Sun, Xiaolin Liu, Andy Tsun, Tianhang Zhai. A novel fully human anti-TIGIT and PVRIG bispecific antibody that elicits potent anti-tumor efficacy in pre-clinical studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5527.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
脑洞疼应助子明采纳,获得10
刚刚
小菜鸡完成签到,获得积分10
刚刚
崽崽发布了新的文献求助30
刚刚
1秒前
1秒前
等等发布了新的文献求助20
1秒前
2秒前
宋宋宋2发布了新的文献求助10
2秒前
圈圈完成签到,获得积分20
3秒前
3秒前
忧伤的幼蓉完成签到,获得积分10
4秒前
cjhsci发布了新的文献求助10
7秒前
GUESSSS发布了新的文献求助10
7秒前
lili发布了新的文献求助10
8秒前
yy完成签到,获得积分10
8秒前
纯真小伙发布了新的文献求助10
9秒前
11秒前
11秒前
福同学完成签到,获得积分10
13秒前
所所应助zzz采纳,获得10
13秒前
疯狂的鲜花完成签到,获得积分10
15秒前
狄百招发布了新的文献求助10
15秒前
16秒前
Golden发布了新的文献求助10
17秒前
19秒前
俏皮书白完成签到,获得积分10
20秒前
keyanlese发布了新的文献求助10
22秒前
烟花应助lili采纳,获得10
23秒前
24秒前
NexusExplorer应助研究僧采纳,获得10
26秒前
26秒前
zxy关注了科研通微信公众号
26秒前
28秒前
tina完成签到,获得积分20
28秒前
28秒前
Lee关闭了Lee文献求助
28秒前
29秒前
斯文败类应助等等采纳,获得10
31秒前
高分求助中
Manual of Clinical Microbiology, 4 Volume Set (ASM Books) 13th Edition 1000
Teaching Social and Emotional Learning in Physical Education 900
Chinese-English Translation Lexicon Version 3.0 500
Electronic Structure Calculations and Structure-Property Relationships on Aromatic Nitro Compounds 500
マンネンタケ科植物由来メロテルペノイド類の網羅的全合成/Collective Synthesis of Meroterpenoids Derived from Ganoderma Family 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 440
Plesiosaur extinction cycles; events that mark the beginning, middle and end of the Cretaceous 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2383063
求助须知:如何正确求助?哪些是违规求助? 2090168
关于积分的说明 5253417
捐赠科研通 1817095
什么是DOI,文献DOI怎么找? 906505
版权声明 558965
科研通“疑难数据库(出版商)”最低求助积分说明 484013